Pergoveris Market Report 2026

Pergoveris Market Overview

• The Pergoveris market growth in the historic period has been driven by increasing diagnosis of gonadotropin deficiencies, expansion of assisted reproductive clinics • Market expansion is supported by increasing demand for advanced ivf protocols, rising focus on precision hormone therapy • Growth Driver: Rising Prevalence Of Infertility Driving Growth In The Market • Market Trend: Adoption of Priority Review Filings in the Pergoveris Market to Expand Access to IVF Treatments • Europe was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pergoveris Market?

Pergoveris is a biologic drug used in fertility treatments to stimulate ovarian function in women with severe gonadotropin deficiency, a condition where the body produces insufficient amounts of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). It is a combination of recombinant FSH and LH, which are critical hormones for stimulating the ovaries to produce mature eggs for assisted reproductive technologies such as in vitro fertilization (IVF). Pergoveris helps to promote follicular growth and ovulation in women who are undergoing fertility treatments. The main formulations in the pergoveris market are injectable pen and vial formulation. The Pergoveris injectable pen is a device used to administer Pergoveris, a combination of recombinant follicle-stimulating hormone (FSH) and luteinizing hormone (LH), for fertility treatments. The various indications include anovulation and assisted reproductive technology (ART) procedures, and several distribution channels including hospitals pharmacies, retail pharmacies, and online pharmacies. The different end uses encompass hospitals, clinics, ambulatory care, and home care.

What Is The Pergoveris Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for advanced ivf protocols, rising focus on precision hormone therapy, expansion of fertility tourism, growing adoption of patient-friendly injectable formats, increasing investments in reproductive biotechnology. Major trends in the forecast period include increasing adoption of recombinant hormone therapies, rising demand for ivf and art procedures, growing use of injectable pen formulations, expansion of precision-controlled fertility treatments, enhanced focus on hormone deficiency management.

Global Pergoveris Market Segmentation

1) By Formulation: Injectable Pen, Vial Formulation 2) By Indication: Anovulation, Assisted Reproductive Technology (ART) Procedures 3) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies 4) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care

What Are The Drivers Of The Pergoveris Market?

The increasing prevalence of infertility is expected to boost the growth of the pergoveris market going forward. Infertility refers to the inability to conceive or maintain a pregnancy or to carry it to term. Infertility is on the rise due to factors such as delayed childbearing, lifestyle choices, environmental toxins, and the increasing prevalence of medical conditions such as polycystic ovary syndrome (PCOS) and endometriosis. Pergoveris helps infertility patients by stimulating ovarian function through a combination of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), promoting the development of eggs in women with severe gonadotropin deficiency. For instance, in April 2023, according to the World Health Organization, a Switzerland-based intergovernmental organization, approximately 17.5% of the global adult population, or about 1 in 6 individuals, face infertility. Thus, the increasing prevalence of infertility is driving the growth of the pergoveris industry. Increasing adoption of IVF procedures is expected to propel the growth of the pergoveris market going forward. IVF procedures refer to medical treatments that assist individuals or couples in conceiving by fertilizing an egg with sperm outside the body and implanting the resulting embryo into the uterus. Adoption of IVF procedures is increasing as more people delay parenthood due to career, education, or social reasons, resulting in age-related fertility decline and greater reliance on fertility treatments. Pergoveris plays a crucial role in increasing adoption of IVF procedures by supporting controlled ovarian stimulation and improving pregnancy outcomes for patients with low ovarian response. For instance, in June 2025, according to the Human Fertilisation & Embryology Authority, a UK-based independent regulator of fertility treatment, reported that, in 2023, 52,400 patients had over 77,500 in vitro fertilization (IVF) cycles at licensed fertility clinics in the UK. Egg freezing cycles increased from 4,700 in 2022 to 6,900 in 2023, accounting for 7% of all cycles. Therefore, increasing adoption of IVF procedures is driving the growth of the pergoveris industry.

Key Players In The Global Pergoveris Market

Major companies operating in the pergoveris market are Merck KGaA

Global Pergoveris Market Trends and Insights

Major companies are operating in the pergoveris market, focusing on developing regulatory and access-oriented advancements, such as priority-review filings under the FDA Commissioner’s National Priority Voucher (CNPV) program, to reduce approval timelines, expand patient access, and improve affordability for complex fertility therapies. A priority-review filing allows regulators to shorten the standard 10–12 month review period to 1–2 months, enabling faster availability of innovative reproductive treatments while maintaining safety and efficacy. For instance, in October 2025, EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, filed Pergoveris® under the FDA CNPV program. The therapy combines recombinant human follicle-stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH) in a 2:1 ratio, delivered via a pre-filled Redi-ject® pen to simplify dosing, reduce injections, and enhance patient experience. Pergoveris is designed to mimic natural reproductive physiology, supporting follicular development and maturation in medically assisted reproductive cycles. The program also aligns with public-private partnerships and direct-to-consumer access initiatives, improving affordability and expanding treatment options for women with severe FSH/LH deficiency.

Regional Insights

Europe was the largest region in the pergoveris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Pergoveris Market?

The pergoveris market consists of sales of pergoveris 150 IU/75 IU, pergoveris 300 IU/150 IU, and pre-filled syringes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pergoveris Market Report 2026?

The pergoveris market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pergoveris industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.